智通财经网·2025-09-15 08:52Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (commercial name: Fuzhuoning) for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] Group 1: Drug Approval Details - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1] - FCN-437c is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights owned by the group [1] - The drug is characterized as an oral, potent, highly selective, and structurally novel small molecule [1] Group 2: Development Background - FCN-437c was included in the national "Major New Drug Creation" science and technology major project in 2018 [1]